APLS (Apellis) Pangali Forward P/E

Apellis Pharmaceuticals (APLS) possesses significant pricing power due to the exclusivity of its drug Syfovre. The company's forward P/E ratio history reflects institutional demand dynamics, where the current status is 0.00. The company dictates terms within the rare eye pathology therapy segment, leveraging inelastic demand. Risks are minimized through portfolio diversification with innovative treatments for blood and vision disorders.

apellis.com - Rasio prakiraan rega marang bathi APLS (periode 04.07.2022 - 30.05.2026)

Rincian analitis lan laporan data perusahaan Apellis Corp (APLS)

- rega saiki lan proyeksi nilai saham:

Kutipan saham Apellis|APLS - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Apellis Pharmaceuticals, Inc.|APLS - Total Nilai Perusahaan

- informasi kapitalisasi buku:

Nilai Akuntansi saben Saham Apellis Pharmaceuticals|APLS - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku apellis.com|APLS - Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Utang marang Ekuitas Apellis Pharmaceuticals|APLS - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Apellis Pharmaceuticals|APLS - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Apellis Pharmaceuticals, Inc.|APLS - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Apellis Pharmaceuticals|Likuiditas cepet apellis.com

- rincian asil keuangan lan kelipatan valuasi:

APLS - Bathi resik perusahaan|Bathi sing dikarepake Apellis Pharmaceuticals|APLS - Rasio rega marang bathi|Pangali Forward P/E Apellis Pharmaceuticals Inc|APLS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Apellis Pharmaceuticals, Inc.|APLS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Apellis Pharmaceuticals|APLS - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan apellis.com|APLS - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Apellis Pharmaceuticals

Analisis komprehensif perusahaan:APLS Apellis

A conservative analysis of Apellis Pharmaceuticals (APLS) requires comparing the current share price with projected forward earnings to avoid overpaying for the asset. By examining the company's expected P/E multiple, an investor can see how the diversification of therapeutic platforms in ophthalmology and systemic diseases mitigates risks, stabilizing future revenues and creating a more resilient investment profile for the business.

Analisis pesaing Apellis Pharmaceuticals

Prakiraan rega marang bathi ALC (Alcon)|BLCO (Bausch & Lomb) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E GKOS (Glaukos Corp.)|Belite Bio (BLTE) - Rasio prakiraan rega marang bathi|OCUL: Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi harrowinc.com|VRDN: Pangali Forward P/E|Rasio prakiraan rega marang bathi LENZ Therapeutics Inc (LENZ)|Rega marang bathi mangsa ngarep Oaktree Specialty Lending|EyePoint Corp (EYPT) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E KOD|Pangali Forward P/E aldeyra.com (ALDX)|Rega marang bathi mangsa ngarep KALA BIO KALA|IRD (Opus Genetics, Inc.) - Rasio rega marang bathi sing dikarepake|OKYO Pharma Inc - Pangali Forward P/E|Rasio prakiraan rega marang bathi Adverum Biotechnologies|Outlook Therapeutics (OTLK) - Rega marang bathi mangsa ngarep|CLSD (clearsidebio.com) - Rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep NovaBay Pharmaceuticals Inc.|Rega marang bathi mangsa ngarep KPRX|Pangali Forward P/E ALIM|Kapitalisasi marang proyeksi bathi eyenovia.com|Rega marang bathi mangsa ngarep Guardion Health Science GHSI|Kapitalisasi marang proyeksi bathi ocuphire.com (OCUP)|OPT: Prakiraan rega marang bathi